NeuroPace, Inc. Stock

Equities

NPCE

US6412881053

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 16:00:00 2024-05-31 EDT 5-day change 1st Jan Change
6.91 USD +5.66% Intraday chart for NeuroPace, Inc. -8.23% -32.98%
Sales 2024 * 75.85M 103M Sales 2025 * 89.24M 122M Capitalization 199M 271M
Net income 2024 * -33M -44.95M Net income 2025 * -29M -39.5M EV / Sales 2024 * 2.92 x
Net Debt 2024 * 22.63M 30.82M Net Debt 2025 * 43.9M 59.79M EV / Sales 2025 * 2.72 x
P/E ratio 2024 *
-5.94 x
P/E ratio 2025 *
-6.9 x
Employees 181
Yield 2024 *
-
Yield 2025 *
-
Free-Float 80.19%
More Fundamentals * Assessed data
Dynamic Chart
1 day+5.66%
1 week-8.23%
1 month-50.29%
3 months-56.79%
6 months-22.36%
Current year-32.98%
More quotes
1 week
6.49
Extreme 6.49
7.88
1 month
6.49
Extreme 6.49
13.89
Current year
6.49
Extreme 6.49
18.15
1 year
3.80
Extreme 3.8
18.15
3 years
1.22
Extreme 1.22
25.75
5 years
1.22
Extreme 1.22
27.38
10 years
1.22
Extreme 1.22
27.38
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 23-07-09
Founder 64 97-11-18
Founder 82 97-11-30
Members of the board TitleAgeSince
Director/Board Member 52 21-10-31
Director/Board Member 68 97-11-18
Founder 82 97-11-30
More insiders
Date Price Change Volume
24-05-31 6.91 +5.66% 67,182
24-05-30 6.54 -2.97% 140,664
24-05-29 6.74 -4.94% 166,131
24-05-28 7.09 -5.84% 106,888

Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm

More quotes
NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
6.91 USD
Average target price
17.21 USD
Spread / Average Target
+149.12%
Consensus